Aprogen Medicines Inc. (KRX:007460)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,030.00
+30.00 (1.50%)
Sep 11, 2026, 3:30 PM KST

Aprogen Medicines Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-83,531-70,202-58,079-55,619-98,657-93,920
Depreciation & Amortization
23,26123,59724,30529,07128,39225,262
Loss (Gain) From Sale of Assets
2,8532,786201.14-30.3457.39-
Asset Writedown & Restructuring Costs
806.42739.83801.872,2719,162223.61
Loss (Gain) From Sale of Investments
1,460-1,749-303-341.932,7441,228
Loss (Gain) on Equity Investments
2,28339,375--1,4899,543
Stock-Based Compensation
311.261,1521,7181,613707.672,445
Provision & Write-off of Bad Debts
-204.3384.751,573-8.5-5,001-
Other Operating Activities
3,450-56,850-18,663-19,249-35,587-17,926
Change in Accounts Receivable
-5,1553,558-207.691,7493,395778.84
Change in Inventory
-3,940-4,0301,270-5,024-17,526-8,367
Change in Accounts Payable
4,328-2,683-4,369-3,491-1,8523,378
Change in Income Taxes
-222.7-222.7-217.8935.78770.88
Change in Other Net Operating Assets
-8,49331,4876,761-9,315-2,151-8,155
Operating Cash Flow
-62,794-32,657-44,992-58,156-113,491-84,740
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-3,988-8,994-12,671-25,514-19,610-34,392
Sale of Property, Plant & Equipment
326.84373.3483.042,273131.6540.06
Cash Acquisitions
-0-5,080-127.87-39,940-
Divestitures
2,62158,122300-29,285-
Sale (Purchase) of Intangibles
-5,481-11,931-10,473-29,371-5,209-474.06
Investment in Securities
15,179-59,583-9,486965.6827,26818,390
Other Investing Activities
-33,953-36,702-8,1308,193-1,690-924.3
Investing Cash Flow
-25,296-63,795-40,504-43,45270,172-12,790

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-37,50011,05014,61096,500134,190
Long-Term Debt Issued
-158,83536,35096,546-30,845
Total Debt Issued
48,679196,33547,400111,15696,500165,035
Short-Term Debt Repaid
--12,300-11,350-40,110-7,500-27,000
Long-Term Debt Repaid
--82,560-12,967-8,481-1,873-30,220
Total Debt Repaid
-76,523-94,860-24,317-48,591-9,373-57,220
Net Debt Issued (Repaid)
-27,844101,47523,08362,56587,127107,815
Issuance of Common Stock
2,000-0.765,51530.972,583
Repurchase of Common Stock
-113.53--0.1--15,791-
Dividends Paid
-0.08-0.08----
Other Financing Activities
15,7301,46763,53726,216-561.9-0
Financing Cash Flow
-10,228102,94186,62194,29670,804110,398

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
2,2371,497352.04-72.93-309.074.05
Net Cash Flow
-96,0807,9871,477-7,38527,17612,872

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-66,781-41,651-57,662-83,669-133,101-119,132
Free Cash Flow Growth
------
Free Cash Flow Margin
-48.08%-35.30%-38.41%-55.57%-169.88%-453.05%
Free Cash Flow Per Share
-3226.13-2100.37-3344.16-5314.11-9864.93-10307.07
Levered Free Cash Flow
-55,676-91,444-41,649-21,656-145,21326,095
Unlevered Free Cash Flow
-51,567-88,467-41,019-21,261-139,02239,697

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
4,8122,821630.7242.7610,99211,339
Cash Income Tax Paid
2,1222,921220.01-2,1283,291398.92
Change in Working Capital
-13,48328,1103,454-15,862-17,199-11,594